Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Gastrin secretion in normal subjects and diabetes patients is inhibited by glucagon-like peptide 1: a role in the gastric side effects of GLP-1-derived drugs?

Research output: Contribution to journalJournal articleResearchpeer-review

  1. 3D analysis of the myenteric plexus of the human bowel by X-ray phase-contrast tomography - a future method?

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Colonoscopy adverse events: are we getting the full picture?

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Pathophysiological-based treatments of complications of cirrhosis

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Oral D/L-3-Hydroxybutyrate stimulates cholecystokinin and insulin secretion and slows gastric emptying in healthy males

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Bilio-enteric flow and plasma concentrations of bile acids after gastric bypass and sleeve gastrectomy

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Glucose-dependent Insulinotropic Polypeptide (GIP) reduces bone resorption in patients with type 2 diabetes

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Differential time responses in inflammatory and oxidative stress markers after a marathon: An observational study

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

Background: Randomized and controlled trials of glucagon-like peptide-1 (GLP-1) derived drugs have shown that the most frequent adverse symptoms are gastrointestinal. Some of the side effects such as dyspepsia, nausea and upper abdominal pain may well be of gastric origin. Since the antral hormone gastrin regulates gastric secretion of acid and enzymes and contributes to the regulation of gastric motility, we examined the effect of GLP-1 on the secretion of gastrin in normal subjects and diabetes patients.Method: Plasma was sampled from ten healthy subjects and ten patients with diabetes mellitus type 1 with glucose clamped between 6 and 9 mM. GLP-1 or saline were infused for 4 h during and after a meal. Plasma concentrations of gastrin and GLP-1 were measured using specific radioimmunoassays.Results: Basal plasma concentrations of gastrin were similar in controls and patients. After the meal, the gastrin concentrations rose significantly during saline infusion, whereas the GLP-1 infusion suppressed the secretion of gastrin significantly, most pronounced in the diabetes patients.Conclusions: The results show that GLP-1 infusion suppresses the postprandial secretion of gastrin in normal subjects and even more so in the diabetes patients. The results may therefore shed further light on the upper gastrointestinal side effects of GLP-1-derived drugs in diabetic patients.

Original languageEnglish
JournalScandinavian Journal of Gastroenterology
Volume54
Issue number12
Pages (from-to)1448-1451
Number of pages4
ISSN0036-5521
DOIs
Publication statusPublished - 2 Dec 2019

ID: 58382529